









DECEMBER 2013, Vol. 14, No. 4   SAJHIVMED     176 
Background. The majority of HIV-positive women in South Africa are of reproductive age, and pregnancies among women using antiretroviral 
therapy (ART) are common. However, there are mixed data regarding the impact of ART on pregnancy outcomes.
Objective. To examine the impact of ART on pregnancy outcome according to the timing of initiation of treatment. 
Methods. A retrospective cohort study was conducted among women delivering at a tertiary hospital from 1 October 2008 to 31 March 2009. 
Results. A total of 245 mothers were receiving ART: 76 mothers (31%) started ART pre-conception and 169 mothers (69%) started ART after 
the first trimester. No significant differences were observed in the rates of preterm delivery and low birth weight (LBW) between the pre- and 
post-conception groups (21% v. 24% and 21% v. 25%, respectively). 
Conclusion. In this cohort of women receiving ART in pregnancy, timing of ART initiation did not have any adverse effect on the measured 
pregnancy outcomes such as preterm delivery and LBW.
S Afr J HIV Med 2013;14(4):176-178. DOI:10.7196/SAJHIVMED.834
ORIGINAL ARTICLE
Impact of antiretroviral therapy on 
pregnancy outcomes 
C D Aniji,1  FCOG (SA); O A Towobola,1 PhD; M E Hoque,2 MSc; T J Mashamba,1 MB ChB; S Monokoane,1 FCOG (SA) 
1 Department of Obstetrics and Gynaecology, University of Limpopo, Medunsa Campus, Pretoria, South Africa
2 Graduate School of Business and Leadership, University of KwaZulu-Natal, Westville Campus, Durban, South Africa
Corresponding author: M E Hoque (muhammad.ehsanul@gmail.com)
South Africa (SA), like many countries in sub-Saharan 
Africa, has a high HIV disease burden. According to 
2008 reports by the World Health Organization (WHO) 
and the Joint United Nations Programme on HIV and 
AIDS (UNAIDS), an estimated 6 million adults and 
children were living with HIV in SA by the end of 2007, including 
approximately 3.2 million (54%) women aged ≥15 years. [1,2] This has 
a significant impact on vertical transmission and maternal mortality. 
The Fourth Report on Confidential Enquiries into Maternal Deaths in 
South Africa 2005 - 2007 showed that pregnancy-unrelated infections, 
mostly HIV/AIDS, were res ponsi ble for 43.7% of all reported maternal 
deaths.[3-5]
Varied results have been reported on the risk of adverse pregnancy 
outcomes in HIV-positive women treated with antiretroviral therapy 
(ART). Several studies from Europe have suggested that the initiation 
of ART during pregnancy may be associated with an increased risk of 
preterm delivery, particularly with protease inhibitor (PI)-containing 
regimens. [6-8] However, these findings have been contradicted by studies 
from Brazil and North America showing no association between 
maternal ART use and pregnancy outcomes.[9-12] 
In Africa, there have been some studies that evaluated the impact 
of ART on pregnancy outcomes. In a Cote d’Ivoire study[13] it was 
highlighted that ART in pregnant women with advanced HIV disease 
substantially reduced mother-to-child transmission, but was associated 
with low birth weight (LBW).  A matched case-control study conducted 
in Nigeria[14] found that HIV-positive women were significantly more 
likely to have intrauterine growth restriction, preterm labour and LBW 
babies than HIV-negative women.
Given the large number of HIV-positive pregnant women in SA, and 
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this population, it is pertinent to investigate any effects that ART may 
have on pregnancy outcomes. 
The aim of this study was to investigate the impact of ART on 
pregnancy outcome, according to the timing of initiation of treatment, 
in a cohort of HIV-positive pregnant women at Dr George Mukhari 
Hospital (DGMH) in Ga-Rankuwa, SA.
Methods
We performed a retrospective medical record review of HIV-positive 
pregnant women who delivered at DGMH from 1 October 2008 
to 31 March 2009. DGMH has a large academic obstetric unit with 
approximately 8 500 deliveries per annum. The study included HIV-
positive pregnant women who booked at the antenatal clinic at DGMH 
and had either been receiving ART before pregnancy (pre-conception 
ART group) or started ART after the first trimester of pregnancy (post-
conception ART group). Women with multiple pregnancies and those 
who defaulted ART and/or antenatal clinic visits were excluded from 
the analysis.
Data on demographic and obstetric characteristics and ART use were 
collected from the labour ward delivery register, patients’ antenatal 
cards and/or hospital records. Data were analysed using SPSS (version 
17.0). Term delivery was defined as birth at a gestational age of ≥37 
weeks, where ultrasound was used to date the pregnancy before 20 
weeks’ gestation; or a birth weight of ≥2 500g in cases where pregnancy 
was not dated with ultrasound before 20 weeks’ gestation. All statistical 
tests were performed using two-sided tests at the p≤0.05 level of 
significance. 
Ethical approval for the study was obtained from the Medunsa 
Research and Ethics Committee of the University of Limpopo. 
Results
A total of 245 mothers were receiving ART during the study period; 
76 (31%) were receiving ART pre-conception and 169 mothers (69%) 
started ART post conception after the first trimester. The average age 
of the participants was 31 and 29 years in the pre- and post-conception 
groups, respectively (p=0.003). Significantly more women in the post-
conception group were primigravidae than in the pre-conception group 
(18% v. 5%, respectively; p=0.003). The rate of caesarean sections was 
similar in the pre- and post-conception groups (Table 1). 
In the pre-conception group, 73 women were on a regimen of 
two nucleoside reverse transcriptase inhibitors (NRTIs) with a non-
nucleoside reverse transcriptase inhibitor (NNRTI), while 3 women 
were on PI-containing regimens. The duration of treatment prior to 
conception ranged from 4 to 60 months. All the women in this group 
were in relatively good health, with sustained viral suppression prior 
to conception. In the post-conception group, 161 women were using 
two NRTIs with an NNRTI, while 8 women were on PI-containing 
regimens. All women in this group had CD4+ counts <200 cells/µl per 
the national ART guidelines at the time of the study. The duration of 
treatment before delivery ranged from 2 to 22 weeks.
Table 2 compares pregnancy outcomes between the two groups. Results 
indicated that preterm delivery rates were similar between the pre- and 
post-conception groups (p=0.348). With regards to LBW, the rate was 
slightly lower (21%) in the pre-conception group than in the post-
conception group (24%), but the difference was not significant (p=0.945).
Discussion
We investigated the effect of ART on pregnancy outcomes according to 
the timing of initiation of treatment. Accordingly, we did not find any 
Table 1. Comparison of maternal age, parity and mode of delivery between the pre- and post-conception 
ART groups
Variable Pre-conception (N=76) Post-conception (N=169) p-value






















ART = antiretroviral therapy; SD = standard deviation.
Table 2. Comparison of gestational age and birth weight between the pre- and post-conception ART groups
Variable Pre-conception (N=76) Post-conception (N=169) p-value








Fetal weight (g),* n (%)
 ≥2 500
 1 500 - 2 499
 1 000 - 1 499










ART = antiretroviral therapy.
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negative impact of this therapy on pregnancy outcomes, regardless of 
the timing of treatment initiation. 
Those women who were receiving ART prior to conception, 
irrespective of the duration of treatment, had a similar rate of preterm 
delivery compared with those who commenced ART after the first 
trimester of pregnancy. A study conducted in the USA[10] also reported 
a non-significant difference in the rate of preterm delivery between 
pre- and post-conception ART groups. It would seem that in this study 
population, the use of antiretrovirals did not have any effect, whether 
positive or negative, on the rate of preterm deliveries. It is important 
to point out that the use of illicit drugs, alcohol abuse and cigarette 
smoking – all important causes of preterm labour – were negligible in 
this setting. 
However, our results are in contrast to the findings of some 
other studies conducted in Europe, Cote d’Ivore and Nigeria, which 
concluded that patients who were receiving ART prior to conception 
had an increased risk of preterm delivery compared with those who 
commenced ART post conception.[8,12-14] 
With regards to LBW in our study, the rates were similar: 17.1% and 
20.7% in the pre- and post-conception groups, respectively. This result 
is in line with other studies conducted in Brazil and the USA,[11,15] both 
of which did not find any association between birth weight and the 
use of ART. However, contrasting results from Europe, Cote d’Ivore 
and Nigeria indicated higher rates of LBW among women receiving 
ART. [8,13,14] 
Study limitations
This was a retrospective study that focused on women delivering live 
infants in health facili ties and did not account for early pregnancy loss or 
home deliveries, thus constituting an important potential bias. Several 
other factors with known influence on pregnancy outcome including 
other infectious diseases, socioeconomic information of the mothers 
(e.g. educational level and employment status) were not measured and 
could not be evaluated in this study. 
Conclusion
In summary, the results of this study suggest that ART initiated before 
or during pregnancy does not have any adverse effect on measured 
pregnancy outcomes such as preterm delivery and LBW. 
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